ClinicalTrials.gg
CompletedNCT01046110BEGIN™Updated Mar 3, 2017Results posted

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

A Phase 3 interventional study of insulin degludec and sitagliptin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 93 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-03.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
23rd of 70
458 · median 384
Started
2010
with 11 others
Phase 3
49 of 70
2 open now
Registered
7th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 12 that started in 2010, is one of 49 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD) treatment, in subjects with type 2 diabetes inadequately controlled with 1-2 OADs (metformin, sulphonylurea, glinides or pioglitazone).

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 458 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes (diagnosed clinically) for at least 6 months
  • Ongoing treatment with 1 or 2 of the following OADs (metformin, insulin secretagogue (sulphonylurea or glinides) or pioglitazone) in any combination with unchanged dosing for at least 3 months prior to Visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination)1500 mg or maximum tolerated dose (at least 1000 mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the maximal daily dose according to local labelling -Pioglitazone: minimum half of the maximal daily dose according to local labelling or maximum tolerated dose
  • (BMI) below or equal to 40.0 kg/m\^2
  • 7.5-11.0 % (both inclusive) by central laboratory analysis

Exclusion criteria

Exclusion Criteria:

  • Use within the last 3 months prior to Visit 1 of: exenatide, liraglutide, rosiglitazone or acarbose
  • Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
  • Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
  • Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
  • Cancer and medical history hereof (except basal cell skin cancer or squamous cell skin cancer)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    IDeg OD

    Drug: insulin degludec

  • Experimental
    DPP-IV inhibitor

    Drug: sitagliptin

Interventions

  • Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.

  • Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change from baseline in HbA1c after 26 weeks of treatment

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG after 26 weeks of treatment

    Time frame: Week 0, Week 26

08

Results

Posted Nov 18, 2015

Participant flow

The trial was conducted at 78 sites in 7 countries: Argentina (2 sites), Canada (11 sites), India (8 sites), Mexico (2 sites), South Africa (3 sites), Turkey (5 sites) and the United States (47 sites).

Participant flow — Overall Study
MilestoneIDeg ODDPP-IV Inhibitor
Started229229
Exposed226228
Completed174174
Not completed5555
Withdrew: Adverse event92
Withdrew: Lack of efficacy01
Withdrew: Protocol violation712
Withdrew: Withdrawal criteria35
Withdrew: Unclassified3635

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change from baseline in HbA1c after 26 weeks of treatment

Time frame:
Week 0, Week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
percentage of glycosylated haemoglobinIDeg ODDPP-IV Inhibitor
Change in Glycosylated Haemoglobin (HbA1c)-1.56 ± 1.09-1.22 ± 1.16
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline in FPG after 26 weeks of treatment

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LIDeg ODDPP-IV Inhibitor
Change in Fasting Plasma Glucose (FPG)-3.22 ± 3.17-1.39 ± 3.11

Adverse events

Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg OD—14/226 (6.2%)44/226 (19.5%)
DPP-IV Inhibitor—10/228 (4.4%)53/228 (23.2%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventIDeg ODDPP-IV Inhibitor
Acute myocardial infarctionCardiac disorders1/2260/228
Cardiac failure congestiveCardiac disorders1/2260/228
CardiomyopathyCardiac disorders1/2260/228
Myocardial infarctionCardiac disorders1/2260/228
ConstipationGastrointestinal disorders1/2260/228
CholelithiasisHepatobiliary disorders1/2260/228
CellulitisInfections and infestations1/2260/228
DiverticulitisInfections and infestations1/2260/228
Lobar pneumoniaInfections and infestations1/2260/228
PneumoniaInfections and infestations1/2260/228
Most frequent other events
Most frequent other events
EventIDeg ODDPP-IV Inhibitor
HeadacheNervous system disorders24/22615/228
DiarrhoeaGastrointestinal disorders13/22619/228
NasopharyngitisInfections and infestations13/22618/228
NauseaGastrointestinal disorders8/22614/228

Baseline characteristics

The full analysis set (FAS) included all randomised patients except for 11 subjects whose site was closed (4 subjects with IDeg; 7 subjects with DPP-IV group/arm). For 4 subjects each in IDeg OD and DPP-IV inhibitor arm, the fasting plasma glucose (FPG) values were missing at baseline.

Age, Continuous
Age, Continuous(years)IDeg ODDPP-IV InhibitorTotal
Mean56.4 ± 10.254.9 ± 11.455.7 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)IDeg ODDPP-IV InhibitorTotal
Female84101185
Male141121262
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDeg ODDPP-IV InhibitorTotal
Mean8.8 ± 1.09.0 ± 1.08.9 ± 1.0
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDeg ODDPP-IV InhibitorTotal
Mean9.4 ± 2.69.9 ± 3.19.7 ± 2.9
09

Study locations

93 sites
  • Novo Nordisk Investigational Site
    Huntsville, Alabama 35801, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90806, United States
  • Novo Nordisk Investigational Site
    Mission Hills, California 91345, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    Torrance, California 90504, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598-3347, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80239-3133, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33765, United States
  • Novo Nordisk Investigational Site
    Inverness, Florida 34452, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33125-1655, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33135, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33186, United States
  • Novo Nordisk Investigational Site
    Ocala, Florida 34471, United States
  • Novo Nordisk Investigational Site
    Ponte Vedra, Florida 32081, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    Columbus, Georgia 31904, United States
  • Novo Nordisk Investigational Site
    Decatur, Georgia 30033, United States
  • Novo Nordisk Investigational Site
    Dunwoody, Georgia 30338, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60611, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60624, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62711, United States
  • Novo Nordisk Investigational Site
    Huntington, Indiana 46750-1404, United States
  • Novo Nordisk Investigational Site
    Council Bluffs, Iowa 51501, United States
  • Novo Nordisk Investigational Site
    Des Moines, Iowa 50314-2610, United States
  • Novo Nordisk Investigational Site
    Paducah, Kentucky 42003, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Brockton, Massachusetts 02301, United States
  • Novo Nordisk Investigational Site
    Livonia, Michigan 48152-3501, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48085-5524, United States
  • Novo Nordisk Investigational Site
    St. Paul, Minnesota 55108, United States
  • Novo Nordisk Investigational Site
    Jackson, Mississippi 39216, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87108, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87131, United States
  • Novo Nordisk Investigational Site
    New Hyde Park, New York 11042, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Durham, North Carolina 27710, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834-5784, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224-2215, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • Novo Nordisk Investigational Site
    Charleston, South Carolina 29401, United States
  • Novo Nordisk Investigational Site
    Murrells Inlet, South Carolina 29576, United States
  • Novo Nordisk Investigational Site
    Corpus Christi, Texas 78404, United States
  • Novo Nordisk Investigational Site
    El Paso, Texas 79905-2709, United States
  • Novo Nordisk Investigational Site
    El Paso, Texas 79912, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77070, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Tomball, Texas 77375, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Virginia Beach, Virginia 23454, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99208, United States
  • Novo Nordisk Investigational Site
    Buenos Aires, C1181ACH, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1440AAD, Argentina
  • Novo Nordisk Investigational Site
    Ciudad Autónoma de BsAs, C1406FWY, Argentina
  • Novo Nordisk Investigational Site
    Córdoba, 5000, Argentina
  • Novo Nordisk Investigational Site
    Mar del Plata, B7602CBM, Argentina
  • Novo Nordisk Investigational Site
    Mendoza, 5500, Argentina
  • Novo Nordisk Investigational Site
    Surrey, British Columbia V3S 2N6, Canada
  • Novo Nordisk Investigational Site
    Cambridge, Ontario N1R 7L6, Canada
  • Novo Nordisk Investigational Site
    Chatham, Ontario N7L 1C1, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6H 4P2, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6P 1A9, Canada
  • Novo Nordisk Investigational Site
    Smiths Falls, Ontario K7A 4W8, Canada
  • Novo Nordisk Investigational Site
    St.Catharines, Ontario L2N 7H8, Canada
  • Novo Nordisk Investigational Site
    Gatineau, Quebec J8V 2P5, Canada
  • Novo Nordisk Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H3J 2V5, Canada
  • Novo Nordisk Investigational Site
    St-Marc-des-Carrières, Quebec G0A 4B0, Canada
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500 001, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka 560 003, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka BANGALORE, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400008, India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600029, India
  • Novo Nordisk Investigational Site
    Madurai, Tamil Nadu 625 020, India
  • Novo Nordisk Investigational Site
    Nagpur, 440012, India
  • Novo Nordisk Investigational Site
    Pune, 411005, India
  • Novo Nordisk Investigational Site
    Pune, 411011, India
  • Novo Nordisk Investigational Site
    Guadalajara, 44600, Mexico
  • Novo Nordisk Investigational Site
    Mexico City, 11850, Mexico
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4001, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7460, South Africa
  • Novo Nordisk Investigational Site
    Umhlanga, 4320, South Africa
  • Novo Nordisk Investigational Site
    Ankara, 06100, Turkey
  • Novo Nordisk Investigational Site
    Denizli, 20070, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34098, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34390, Turkey
  • Novo Nordisk Investigational Site
    Izmir, 35340, Turkey
10

References and documents

Publications

  • Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjoth TV, Rasmussen S, Garber AJ. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab. 2013 Aug;15(8):760-6. doi: 10.1111/dom.12115. Epub 2013 May 6. PubMed 23577643 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 5 years after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2010
First posted
Jan 11, 2010
Start
Jan 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results delay requested
Feb 24, 2011
Results first posted
Nov 18, 2015
Last update
Mar 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01046110
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 11, 2010
Start date
Jan 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Nov 18, 2015
Last update
Mar 3, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Sitagliptin

Start the discussion